SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.
![](https://u.jimcdn.com/cms/o/s0f1b75a93752b41c/userlayout/img/mv-nasal-head-pc.png?t=1522208673)
![](https://u.jimcdn.com/cms/o/s0f1b75a93752b41c/userlayout/img/mv-expertise-nose.png?t=1522208651)
![](https://u.jimcdn.com/cms/o/s0f1b75a93752b41c/userlayout/img/mv-expertise-drug.png?t=1522208635)
![](https://u.jimcdn.com/cms/o/s0f1b75a93752b41c/userlayout/img/mv-expertise-device.png?t=1522208629)
![](https://u.jimcdn.com/cms/o/s0f1b75a93752b41c/userlayout/img/mv-expertise-face.png?t=1522208645)
3D Nasal Cast Model
For Admin
Satsuma Pharmaceuticals, Inc. (Satsuma) was established in the US by SNBL primarily for the purpose of furthering the development of a migraine treatment drug (dihydroergotamine, DHE) applying SNBL licensing platform technology related to the development of a nasal DHE product (STS101).
Satsuma was listed on the NASDAQ in the United States on September 13, 2019.
Satsuma completed Phase III clinical trials for STS101 in 2022 and submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (“FDA”) in March 2023.
On April 16, 2023, SNBL announced that it had entered into a definitive agreement to acquire Satsuma and as a result of the completion of the transaction, Satsuma will become a consolidated subsidiary of SNBL.
With the acquisition of Satsuma, SNBL will acquire exclusive worldwide rights to develop, manufacture and commercialize STS101.